vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). Grand Canyon Education, Inc. runs the higher net margin — 28.1% vs 11.1%, a 17.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 5.3%). Grand Canyon Education, Inc. produced more free cash flow last quarter ($122.9M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
ANIP vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $308.1M |
| Net Profit | $27.5M | $86.7M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 35.1% |
| Net Margin | 11.1% | 28.1% |
| Revenue YoY | 29.6% | 5.3% |
| Net Profit YoY | 367.5% | 5.9% |
| EPS (diluted) | $1.14 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $308.1M | ||
| Q3 25 | $227.8M | $261.1M | ||
| Q2 25 | $211.4M | $247.5M | ||
| Q1 25 | $197.1M | $289.3M | ||
| Q4 24 | $190.6M | $292.6M | ||
| Q3 24 | $148.3M | $238.3M | ||
| Q2 24 | $138.0M | $227.5M | ||
| Q1 24 | $137.4M | $274.7M |
| Q4 25 | $27.5M | $86.7M | ||
| Q3 25 | $26.6M | $16.3M | ||
| Q2 25 | $8.5M | $41.5M | ||
| Q1 25 | $15.7M | $71.6M | ||
| Q4 24 | $-10.3M | $81.9M | ||
| Q3 24 | $-24.2M | $41.5M | ||
| Q2 24 | $-2.3M | $34.9M | ||
| Q1 24 | $18.2M | $68.0M |
| Q4 25 | 14.1% | 35.1% | ||
| Q3 25 | 15.9% | 6.9% | ||
| Q2 25 | 6.6% | 20.9% | ||
| Q1 25 | 13.3% | 30.4% | ||
| Q4 24 | -2.3% | 34.2% | ||
| Q3 24 | -13.8% | 20.2% | ||
| Q2 24 | 3.7% | 18.8% | ||
| Q1 24 | 14.8% | 30.8% |
| Q4 25 | 11.1% | 28.1% | ||
| Q3 25 | 11.7% | 6.2% | ||
| Q2 25 | 4.0% | 16.8% | ||
| Q1 25 | 8.0% | 24.8% | ||
| Q4 24 | -5.4% | 28.0% | ||
| Q3 24 | -16.3% | 17.4% | ||
| Q2 24 | -1.7% | 15.3% | ||
| Q1 24 | 13.2% | 24.8% |
| Q4 25 | $1.14 | $3.13 | ||
| Q3 25 | $1.13 | $0.58 | ||
| Q2 25 | $0.36 | $1.48 | ||
| Q1 25 | $0.69 | $2.52 | ||
| Q4 24 | $-0.45 | $2.83 | ||
| Q3 24 | $-1.27 | $1.42 | ||
| Q2 24 | $-0.14 | $1.19 | ||
| Q1 24 | $0.82 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $111.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $746.9M |
| Total Assets | $1.4B | $992.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $111.8M | ||
| Q3 25 | $262.6M | $97.3M | ||
| Q2 25 | $217.8M | $192.3M | ||
| Q1 25 | $149.8M | $144.5M | ||
| Q4 24 | $144.9M | $324.6M | ||
| Q3 24 | $145.0M | $263.6M | ||
| Q2 24 | $240.1M | $241.3M | ||
| Q1 24 | $228.6M | $196.2M |
| Q4 25 | $540.7M | $746.9M | ||
| Q3 25 | $505.8M | $758.0M | ||
| Q2 25 | $436.8M | $778.0M | ||
| Q1 25 | $418.6M | $780.7M | ||
| Q4 24 | $403.7M | $783.9M | ||
| Q3 24 | $405.9M | $764.1M | ||
| Q2 24 | $455.8M | $759.2M | ||
| Q1 24 | $452.0M | $759.4M |
| Q4 25 | $1.4B | $992.3M | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $992.9M | ||
| Q2 24 | $920.8M | $992.7M | ||
| Q1 24 | $914.5M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $130.5M |
| Free Cash FlowOCF − Capex | $29.1M | $122.9M |
| FCF MarginFCF / Revenue | 11.8% | 39.9% |
| Capex IntensityCapex / Revenue | 0.5% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $130.5M | ||
| Q3 25 | $44.1M | $-48.6M | ||
| Q2 25 | $75.8M | $124.0M | ||
| Q1 25 | $35.0M | $67.6M | ||
| Q4 24 | $15.9M | $135.8M | ||
| Q3 24 | $12.5M | $-29.4M | ||
| Q2 24 | $17.4M | $98.6M | ||
| Q1 24 | $18.3M | $85.0M |
| Q4 25 | $29.1M | $122.9M | ||
| Q3 25 | $38.0M | $-58.3M | ||
| Q2 25 | $71.8M | $115.4M | ||
| Q1 25 | $32.5M | $58.7M | ||
| Q4 24 | $13.5M | $126.1M | ||
| Q3 24 | $7.7M | $-39.0M | ||
| Q2 24 | $13.0M | $89.6M | ||
| Q1 24 | $13.7M | $76.0M |
| Q4 25 | 11.8% | 39.9% | ||
| Q3 25 | 16.7% | -22.3% | ||
| Q2 25 | 34.0% | 46.6% | ||
| Q1 25 | 16.5% | 20.3% | ||
| Q4 24 | 7.1% | 43.1% | ||
| Q3 24 | 5.2% | -16.3% | ||
| Q2 24 | 9.4% | 39.4% | ||
| Q1 24 | 10.0% | 27.7% |
| Q4 25 | 0.5% | 2.5% | ||
| Q3 25 | 2.7% | 3.7% | ||
| Q2 25 | 1.9% | 3.5% | ||
| Q1 25 | 1.3% | 3.1% | ||
| Q4 24 | 1.3% | 3.3% | ||
| Q3 24 | 3.2% | 4.0% | ||
| Q2 24 | 3.2% | 3.9% | ||
| Q1 24 | 3.3% | 3.3% |
| Q4 25 | 1.10× | 1.50× | ||
| Q3 25 | 1.66× | -2.99× | ||
| Q2 25 | 8.87× | 2.98× | ||
| Q1 25 | 2.23× | 0.94× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | -0.71× | ||
| Q2 24 | — | 2.83× | ||
| Q1 24 | 1.00× | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LOPE
Segment breakdown not available.
